Randall Harris, MD, PhD
Professor Emeritus
Epidemiology
Education
- M.D.
- University of Nebraska, 1983
- Ph.D.
- Genetics, North Carolina State University, 1974
- M.S.
- Genetics, University of Nebraska, 1971
- Board Certifications: Clinical Pathology
- Public Health
Awards and honors
- Fellow, American Association for the Advancement of Science, 2008, for research showing that inhibition of the inducible cyclooxygenase-2 (COX-2) gene has significant anti-neoplastic effects against major forms of cancer.
Additional background
Books
- Harris RE. Global Epidemiology of Cancer, Jones & Bartlett, 2015.
- Harris RE. Epidemiology of Chronic Disease: Global Perspectives, Jones & Bartlett, 2012.
- Harris RE. Inflammation in the Pathogenesis of Chronic Diseases: the COX-2 Controversy, Springer, 2007.
- Harris RE. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, 2003.
Select publications
- Kennedy BM, Harris RE (2018). Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer. Inflammopharmacology. 2018 May 7. doi: 10.1007/s10787-018-0489-6.
- Harris RE, Beebe J, Schwartzbaum J (2020). Chemoprevention of breast cancer by lipoxygenase and cyclooxygenase inhibitors. World Academy of Sciences Journal 2020; 2(1), 14-18, https://doi.org/10.3892/wasj.2020.34.
- Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World Journal of Clinical Oncology 5(4): 677-692, 2014.
- Harris RE, Beebe J, Al Shafie GA. Reduction in cancer risk by selective and non-selective cyclooxygenase 2 (COX-2) inhibitors. J Exp Pharm, 4, 91-96, 2012.
- Harris RE. Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammo-pharmacology. 17:1-13, 2009.
- Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and non-selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 8 (237): Aug 14, 2008.
- Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase-2 (COX-2) blockade: results of a case control study. International Journal of Biological Sciences, 3(5): 328-334, 2007
- Harris RE. COX-2 and the inflammogenesis of cancer. Subcellular Biochemistry, 42: 193-212, 2007.
- Harris RE, Beebe-Donk JD, Alshafie GA. Cancer chemoprevention by selective cyclooxygenase-2 (COX-2) blockade: results of case control studies. Subcellular Biochemistry, 42: 83-126, 2007.
- Harris RE; Beebe-Donk J; Alshafie GA. Reduction in the risk of human breast cancer by COX-2 inhibitors. Biomed Central (BMC). Cancer, 6:27, 2006.